- Home
- RYOJ vs GLTO Comparison
RYOJ vs GLTO Comparison
Compare RYOJ & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYOJ
- GLTO
- Stock Information
- Founded
- RYOJ 2015
- GLTO 2011
- Country
- RYOJ Japan
- GLTO Denmark
- Employees
- RYOJ N/A
- GLTO N/A
- Industry
- RYOJ Professional Services
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- RYOJ Consumer Discretionary
- GLTO Health Care
- Exchange
- RYOJ Nasdaq
- GLTO Nasdaq
- Market Cap
- RYOJ 24.2M
- GLTO 23.7M
- IPO Year
- RYOJ 2025
- GLTO 2020
- Fundamental
- Price
- RYOJ $4.18
- GLTO $26.31
- Analyst Decision
- RYOJ
- GLTO
- Analyst Count
- RYOJ 0
- GLTO 0
- Target Price
- RYOJ N/A
- GLTO N/A
- AVG Volume (30 Days)
- RYOJ 1.3M
- GLTO 3.1M
- Earning Date
- RYOJ 11-28-2025
- GLTO 11-06-2025
- Dividend Yield
- RYOJ N/A
- GLTO N/A
- EPS Growth
- RYOJ 72.91
- GLTO N/A
- EPS
- RYOJ 0.13
- GLTO N/A
- Revenue
- RYOJ $11,576,848.00
- GLTO N/A
- Revenue This Year
- RYOJ N/A
- GLTO N/A
- Revenue Next Year
- RYOJ N/A
- GLTO N/A
- P/E Ratio
- RYOJ $32.57
- GLTO N/A
- Revenue Growth
- RYOJ 5.60
- GLTO N/A
- 52 Week Low
- RYOJ $1.81
- GLTO $2.01
- 52 Week High
- RYOJ $11.43
- GLTO $33.60
- Technical
- Relative Strength Index (RSI)
- RYOJ N/A
- GLTO 77.29
- Support Level
- RYOJ N/A
- GLTO $15.00
- Resistance Level
- RYOJ N/A
- GLTO $29.03
- Average True Range (ATR)
- RYOJ 0.00
- GLTO 3.60
- MACD
- RYOJ 0.00
- GLTO 2.19
- Stochastic Oscillator
- RYOJ 0.00
- GLTO 73.89
About RYOJ rYojbaba Co. Ltd. Common Shares
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.